News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Phase Bioscience, Inc. Announces Series B Investment from Johnson & Johnson Development Corporation, Fletcher Spaght Ventures and Hatteras Venture Partners


10/24/2007 12:53:20 PM

DURHAM, N.C.--(BUSINESS WIRE)--Phase Bioscience, Inc., a development stage biotechnology company, announced today that it has successfully raised an additional $5.4 million in Series B financing, bringing the total Series B round to $6.6 million. New investor, Fletcher Spaght Ventures (FSV) co-led the round, joining Series B lead investor, Johnson & Johnson Development Corporation (JJDC), which closed on a first tranche of the financing in December 2006 and invested further in this closing. Founding investor, Hatteras Venture Partners (HVP), reinvested in this Series B round from its new fund. Dr. Guy Fish, Vice President, FSV commented that “biopharmaceutical companies highly value the capabilities of PhaseBio’s innovations.”

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES